ソマトスタチンアナログ
WordNet
- of or related to the anus; "anal thermometer"
- a stage in psychosexual development when the childs interest is concentrated on the anal region; fixation at this stage is said to result in orderliness, meanness, stubbornness, compulsiveness, etc. (同)anal retentive
PrepTutorEJDIC
- 肛門(こうもん)(anus)の
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism.
- Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ, Cherrington AD.Author information Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN.AbstractThe impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious dogs underwent euglycemic clamps with tracer and hepatic balance measurements. Clamp period infusions were peripheral venous regular insulin (0.1 nmol ⋅ kg(-1) ⋅ h(-1) [control], n = 6) or LY (bolus [nmol/kg], continuous [nmol ⋅ kg(-1) ⋅ h(-1)]: 0.5, 0.5 [n = 6]; 0.375, 0.375 [n = 5]; 0.25, 0.25 [n = 4]), somatostatin, and glucose, as well as intraportal glucagon (basal). During the clamp, the dogs switched from net hepatic glucose output to uptake (rates reached 2.1 ± 1.2, 0.9 ± 2.1, 8.6 ± 2.3, and 6.0 ± 1.1 µmol ⋅ kg(-1) ⋅ min(-1) within 5 h in control, LY0.25, LY0.375, and LY0.5, respectively). Non-HGU in LY increased less than in control; the ratio of change from basal in non-HGU to change in net hepatic glucose balance, calculated when glucose infusion rates (GIRs) were ~20 µmol ⋅ kg(-1) ⋅ min(-1) in all groups, was higher in control (1.17 ± 0.38) versus LY0.25 (0.39 ± 0.33), LY0.375 (-0.01 ± 0.13), and LY0.5 (-0.09 ± 0.07). Likewise, the change from baseline in glucose Rd-to-Ra ratio was greatest in control (1.4 ± 0.3 vs. 0.6 ± 0.4, 0.5 ± 0.2, and 0.6 ± 0.2 in LY0.25, LY0.375, and LY0.5, respectively). In contrast to exogenously administered human insulin, LY demonstrated preferential hepatic effects, similar to endogenously secreted insulin. Therefore, the analog might reduce complications associated with current insulin therapy.
- Diabetes.Diabetes.2014 Feb;63(2):494-504. doi: 10.2337/db13-0826. Epub 2013 Oct 2.
- The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious dogs underwent euglycemic clamps with tracer and hepatic balance measurements. Clamp period infusions were peripheral venous regular insulin (0.1 nmol ⋅ kg(-1) ⋅ h(-1)
- PMID 24089512
- Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
- van der Pas R, van Esch JH, de Bruin C, Danser AH, Pereira AM, Zelissen PM, Netea-Maier R, Sprij-Mooij DM, van den Berg-Garrelds IM, van Schaik RH, Lamberts SW, van den Meiracker AH, Hofland LJ, Feelders RA.Author information Division of Endocrinology.AbstractOBJECTIVE/METHODS: Cushing's disease (CD) is often accompanied by hypertension. CD can be treated surgically and, given the expression of somatostatin subtype 5 and dopamine 2 receptors by corticotroph pituitary adenomas, pharmacologically. Indeed, we recently observed that stepwise medical combination therapy with the somatostatin-analog pasireotide, the dopamine-agonist cabergoline, and ketoconazole (which directly suppresses steroidogenesis) biochemically controlled CD patients and lowered their blood pressure after 80 days. Glucocorticoids (GC) modulate the renin-angiotensin-aldosterone system (RAAS) among others by increasing hepatic angiotensinogen expression and stimulating mineralocorticoid receptors (MR). This study therefore evaluated plasma RAAS components in CD patients before and after drug therapy. In addition, we studied whether cabergoline/pasireotide have direct relaxant effects in angiotensin II (Ang II)-constricted iliac arteries of spontaneously hypertensive rats, with and without concomitant GR/MR stimulation with dexamethasone or hydrocortisone.
- European journal of endocrinology / European Federation of Endocrine Societies.Eur J Endocrinol.2014 Feb 1;170(2):181-91. doi: 10.1530/EJE-13-0477. Print 2014 Feb.
- OBJECTIVE/METHODS: Cushing's disease (CD) is often accompanied by hypertension. CD can be treated surgically and, given the expression of somatostatin subtype 5 and dopamine 2 receptors by corticotroph pituitary adenomas, pharmacologically. Indeed, we recently observed that stepwise medical combinat
- PMID 24165019
- Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate.
- Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.Author information Department of Nuclear Medicine, University Hospital, Bonn, Germany.AbstractOutcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET) after peptide receptor radionuclide therapy (PRRT) are still limited, especially with regard to the impact of the Ki-67 index. Using a single-center analysis, we aimed to establish predictors of survival.
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine.J Nucl Med.2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.
- Outcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET) after peptide receptor radionuclide therapy (PRRT) are still limited, especially with regard to the impact of the Ki-67 index. Using a single-center analysis, we aimed to establish predictors of survival.METHOD
- PMID 24434296
Japanese Journal
- 膵がん 膵神経内分泌腫瘍の薬物療法の最近の動向 (特集 肝・胆・膵腫瘍の薬物療法 : 最近の進歩)
- 先端巨大症患者治療後の治癒判定と長期予後 (特集 先端巨大症診療のUp-to-date)
Related Links
- This page tells you about somatostatin analogue treatments for carcinoid. ... Somatostatin analogues Somatostatin is a protein made naturally in the body. It slows down the production of many hormones, including gut hormones and ...
- Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of a novel somatostatin analog (SSA) for the treatment of tumors. ... Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused ...
★リンクテーブル★
[★]
ソマトスタチンアナログ
[★]
ソマトスタチンアナログ
[★]
ソマトスタチンアナログ
[★]
- 関
- analogue、derivate、derivative、relative
linux
| 1
|
YEARLY
|
年別レポート
|
|
| Q
|
QUARTERLY
|
4半期別レポート
|
|
| m
|
MONTHLY
|
月別レポート
|
|
| W
|
WEEKLY
|
週別レポート
|
ON
|
| D
|
DAILYREP
|
日別レポート
|
ON
|
| d
|
DAILYSUM
|
曜日別集計
|
|
| H
|
HOURLYREP
|
時間別レポート
|
ON
|
| h
|
HOURLYSUM
|
時間別集計
|
ON
|
| w
|
WEEKHOUR
|
曜日別時間集計
|
|
| 4
|
QUARTERREP
|
15分間隔レポート
|
ON
|
| 6
|
QUARTERSUM
|
15分間隔集計
|
ON
|
| 5
|
FIVEREP
|
5分間隔レポート
|
|
| 7
|
FIVESUM
|
5分間隔集計
|
|
| S
|
HOST
|
ホストレポート
|
ON
|
| l
|
REDIRHOST
|
ホストリダイレクションレポート
|
ON
|
| L
|
FAILHOST
|
ホスト不成功レポート
|
ON
|
| Z
|
ORGANISATION
|
組織レポート
|
ON
|
| o
|
DOMAIN
|
ドメインレポート
|
ON
|
| r
|
REQUEST
|
リクエストレポート
|
ON
|
| i
|
DIRECTORY
|
ディレクトリレポート
|
ON
|
| t
|
FILETYPE
|
ファイル種類別レポート
|
ON
|
| z
|
SIZE
|
ファイルサイズレポート
|
ON
|
| P
|
PROCTIME
|
処理時間レポート
|
ON
|
| E
|
REDIR
|
リダイレクトレポート
|
ON
|
| I
|
FAILURE
|
不成功レポート
|
ON
|
| f
|
REFERRER
|
リンク元レポート
|
ON
|
| s
|
REFSITE
|
リンク元サイトレポート
|
ON
|
| N
|
SEARCHQUERY
|
検索語句レポート
|
ON
|
| n
|
SEARCHWORD
|
検索語レポート
|
ON
|
| Y
|
INTSEARCHQUERY
|
内部検索語句レポート
|
ON
|
| y
|
INTSEARCHWORD
|
内部検索単語レポート
|
ON
|
| k
|
REDIRREF
|
リダイレクトされたリンク元URLレポート
|
ON
|
| K
|
FAILREF
|
不成功リンク元レポート
|
ON
|
| B
|
FULLBROWSER
|
ブラウザーレポート
|
ON
|
| b
|
BROWSER
|
ブラウザーの概要
|
ON
|
| p
|
OSREP
|
OSレポート
|
ON
|
| v
|
VHOST
|
仮想ホストレポート
|
ON
|
| R
|
REDIRVHOST
|
仮想ホストリダイレクションレポート
|
ON
|
| M
|
FAILVHOST
|
仮想ホスト不成功レポート
|
ON
|
| u
|
USER
|
ユーザレポート
|
ON
|
| j
|
REDIRUSER
|
ユーザリダイレクションレポート
|
ON
|
| J
|
FAILUSER
|
不成功ユーザレポート
|
ON
|
| c
|
STATUS
|
状態コードレポート
|
ON
|
[★]
- 関
- analyse、analyses、analysis、analytical、analyze、ani、anus、assay、dissect